Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by toinv261on Nov 18, 2016 10:21am

176 Views

Post# 25480372

RE:The RPS

Hi anthony evans.

I've reread Sarah's reply and now it seems clear and positive on both sides...Zenith and RVX.

It would certainly increase the attractivesness of Zenith (Zen Capital and Zen Epi), but I hope that only parts of Zen Epi would be sold one or a bundle at a time...e.g. SanFrans' star factory concept.

I hold lots of Zenith and I'm long on RVX and will build when I get $.

One thing I do not understand about my Zenith shares is whether my shares are Royalty Preferred shares or are those shares only for private funders like Eastern? Hope someone can help here.

GLTA Toinv

Bullboard Posts

FE Battery Metals begins 2024 winter drill program